Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $504 thousand versus the consensus estimate of $480 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• Ennis (EBF) Reports In-Line Q1 EPS
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs